Press releases

You will be able to find all of our recent and archived news announcements. Our press releases are intended for business journalists and analysts/investors.

ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment

ViiV Healthcare today announced the start of a phase III programme to support regulatory filings for a two-drug regimen of dolutegravir (Tivicay®) and lamivudine (Epivir®) as a treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy.

Read more - ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment Read more

GSK and Verily to establish Galvani Bioelectronics – a new company dedicated to the development of bioelectronic medicines

GSK (LSE/NYSE: GSK) today announced an agreement with Verily Life Sciences LLC (formerly Google Life Sciences), an Alphabet company, to form Galvani Bioelectronics to enable the research, development and commercialisation of bioelectronic medicines. GSK will hold a 55% equity interest in the new jointly owned company and Verily will hold 45%.

Read more - GSK and Verily to establish Galvani Bioelectronics – a new company dedicated to the development of bioelectronic medicines Read more

ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV

ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy for Triumeq® (dolutegravir/abacavir/lamivudine) compared with atazanavir boosted with ritonavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in 495 treatment-naïve women living with HIV.

Read more - ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV Read more